REGULATORY
Deregulation Panel Proposes Giving Private Companies Access to National Health Database to Promote New Drug Development
The Regulatory Reform Promotion Council issued on June 6 its recommendation to Prime Minister Shinzo Abe, calling for the provisioning of data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) to private companies…
To read the full story
Related Article
- Deregulation Panel Pushes PMDA to Digitalize Process
June 6, 2018
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





